Share
array:23 [ "pii" => "S2173574322001265" "issn" => "21735743" "doi" => "10.1016/j.reumae.2022.02.004" "estado" => "S300" "fechaPublicacion" => "2022-10-01" "aid" => "1615" "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología" "copyrightAnyo" => "2022" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Reumatol Clin. 2022;18:443-52" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S1699258X22001152" "issn" => "1699258X" "doi" => "10.1016/j.reuma.2022.02.009" "estado" => "S300" "fechaPublicacion" => "2022-10-01" "aid" => "1615" "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Reumatol Clin. 2022;18:443-52" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "es" => array:12 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Artículo especial</span>" "titulo" => "Recomendaciones SER-SEPAR para el manejo de la enfermedad pulmonar intersticial difusa asociada a la artritis reumatoide. Parte 1: epidemiología, factores de riesgo y pronóstico" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "443" "paginaFinal" => "452" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "SER-SEPAR recommendations for the management of rheumatoid arthritis-related interstitial lung disease. Part 1: Epidemiology, risk factors and prognosis" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "José Antonio Rodríguez Portal, Noé Brito García, Petra Díaz del Campo Fontecha, Claudia Valenzuela, Ana María Ortiz, M. Asunción Nieto, Natalia Mena-Vázquez, Esteban Cano-Jiménez, Iván Castellví, Myriam Aburto, Gema Bonilla, María Vanesa Hernández Hernández, Félix Manuel Francisco Hernández, María Correyero Plaza, Isabel Castrejón, Miguel Ángel Abad Hernández, Javier Narváez" "autores" => array:17 [ 0 => array:2 [ "nombre" => "José Antonio" "apellidos" => "Rodríguez Portal" ] 1 => array:2 [ "nombre" => "Noé" "apellidos" => "Brito García" ] 2 => array:2 [ "nombre" => "Petra" "apellidos" => "Díaz del Campo Fontecha" ] 3 => array:2 [ "nombre" => "Claudia" "apellidos" => "Valenzuela" ] 4 => array:2 [ "nombre" => "Ana María" "apellidos" => "Ortiz" ] 5 => array:2 [ "nombre" => "M. Asunción" "apellidos" => "Nieto" ] 6 => array:2 [ "nombre" => "Natalia" "apellidos" => "Mena-Vázquez" ] 7 => array:2 [ "nombre" => "Esteban" "apellidos" => "Cano-Jiménez" ] 8 => array:2 [ "nombre" => "Iván" "apellidos" => "Castellví" ] 9 => array:2 [ "nombre" => "Myriam" "apellidos" => "Aburto" ] 10 => array:2 [ "nombre" => "Gema" "apellidos" => "Bonilla" ] 11 => array:2 [ "nombre" => "María Vanesa" "apellidos" => "Hernández Hernández" ] 12 => array:2 [ "nombre" => "Félix Manuel Francisco" "apellidos" => "Hernández" ] 13 => array:2 [ "nombre" => "María" "apellidos" => "Correyero Plaza" ] 14 => array:2 [ "nombre" => "Isabel" "apellidos" => "Castrejón" ] 15 => array:2 [ "nombre" => "Miguel Ángel" "apellidos" => "Abad Hernández" ] 16 => array:2 [ "nombre" => "Javier" "apellidos" => "Narváez" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2173574322001265" "doi" => "10.1016/j.reumae.2022.02.004" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173574322001265?idApp=UINPBA00004M" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1699258X22001152?idApp=UINPBA00004M" "url" => "/1699258X/0000001800000008/v1_202210010847/S1699258X22001152/v1_202210010847/es/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S2173574321002112" "issn" => "21735743" "doi" => "10.1016/j.reumae.2021.06.001" "estado" => "S300" "fechaPublicacion" => "2022-10-01" "aid" => "1561" "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Reumatol Clin. 2022;18:453-8" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>" "titulo" => "JAK kinase inhibitors and varicella zoster virus infection in patients with rheumatoid arthritis. Systematic review of the literature" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "453" "paginaFinal" => "458" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Inhibidores de receptores JAK quinasa e infección por virus varicela zoster en pacientes con artritis reumatoide. Revisión sistemática de la literatura" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1870 "Ancho" => 2508 "Tamanyo" => 237526 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0005" "detalle" => "Fig. " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Flow chart of the studies.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Carmen Olga Sánchez González, Juan Carlos Nieto González" "autores" => array:2 [ 0 => array:2 [ "nombre" => "Carmen Olga" "apellidos" => "Sánchez González" ] 1 => array:2 [ "nombre" => "Juan Carlos" "apellidos" => "Nieto González" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S1699258X21001868" "doi" => "10.1016/j.reuma.2021.06.004" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1699258X21001868?idApp=UINPBA00004M" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173574321002112?idApp=UINPBA00004M" "url" => "/21735743/0000001800000008/v1_202210070758/S2173574321002112/v1_202210070758/en/main.assets" ] "en" => array:21 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Special Article</span>" "titulo" => "SER-SEPAR recommendations for the management of rheumatoid arthritis-related interstitial lung disease. Part 1: Epidemiology, risk factors and prognosis" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "443" "paginaFinal" => "452" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "José Antonio Rodríguez Portal, Noé Brito García, Petra Díaz del Campo Fontecha, Claudia Valenzuela, Ana María Ortiz, M. Asunción Nieto, Natalia Mena-Vázquez, Esteban Cano-Jiménez, Iván Castellví, Myriam Aburto, Gema Bonilla, María Vanesa Hernández Hernández, Félix Manuel Francisco Hernández, María Correyero Plaza, Isabel Castrejón, Miguel Ángel Abad Hernández, Javier Narváez" "autores" => array:17 [ 0 => array:3 [ "nombre" => "José Antonio" "apellidos" => "Rodríguez Portal" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 1 => array:3 [ "nombre" => "Noé" "apellidos" => "Brito García" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] 2 => array:3 [ "nombre" => "Petra" "apellidos" => "Díaz del Campo Fontecha" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] 3 => array:3 [ "nombre" => "Claudia" "apellidos" => "Valenzuela" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] ] ] 4 => array:3 [ "nombre" => "Ana María" "apellidos" => "Ortiz" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">d</span>" "identificador" => "aff0020" ] ] ] 5 => array:3 [ "nombre" => "M. Asunción" "apellidos" => "Nieto" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">e</span>" "identificador" => "aff0025" ] ] ] 6 => array:3 [ "nombre" => "Natalia" "apellidos" => "Mena-Vázquez" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">f</span>" "identificador" => "aff0030" ] ] ] 7 => array:3 [ "nombre" => "Esteban" "apellidos" => "Cano-Jiménez" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">g</span>" "identificador" => "aff0035" ] ] ] 8 => array:3 [ "nombre" => "Iván" "apellidos" => "Castellví" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">h</span>" "identificador" => "aff0040" ] ] ] 9 => array:3 [ "nombre" => "Myriam" "apellidos" => "Aburto" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">i</span>" "identificador" => "aff0045" ] ] ] 10 => array:3 [ "nombre" => "Gema" "apellidos" => "Bonilla" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">j</span>" "identificador" => "aff0050" ] ] ] 11 => array:3 [ "nombre" => "María Vanesa" "apellidos" => "Hernández Hernández" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">k</span>" "identificador" => "aff0055" ] ] ] 12 => array:3 [ "nombre" => "Félix Manuel" "apellidos" => "Francisco Hernández" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">l</span>" "identificador" => "aff0060" ] ] ] 13 => array:3 [ "nombre" => "María" "apellidos" => "Correyero Plaza" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">m</span>" "identificador" => "aff0065" ] ] ] 14 => array:3 [ "nombre" => "Isabel" "apellidos" => "Castrejón" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">n</span>" "identificador" => "aff0070" ] ] ] 15 => array:3 [ "nombre" => "Miguel Ángel" "apellidos" => "Abad Hernández" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">o</span>" "identificador" => "aff0075" ] ] ] 16 => array:4 [ "nombre" => "Javier" "apellidos" => "Narváez" "email" => array:1 [ 0 => "fjnarvaez@bellvitgehospital.cat" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">p</span>" "identificador" => "aff0080" ] 1 => array:2 [ "etiqueta" => "*" "identificador" => "cor0005" ] ] ] ] "afiliaciones" => array:16 [ 0 => array:3 [ "entidad" => "Servicio de Neumología, Hospital Virgen del Rocío, Sevilla, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Unidad de Investigación, Sociedad Española de Reumatología, Madrid, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Servicio de Neumología, Hospital Universitario de La Princesa, Madrid, Spain" "etiqueta" => "c" "identificador" => "aff0015" ] 3 => array:3 [ "entidad" => "Servicio de Reumatología, Hospital Universitario de La Princesa, Madrid, Spain" "etiqueta" => "d" "identificador" => "aff0020" ] 4 => array:3 [ "entidad" => "Servicio de Neumología, Hospital Clínico San Carlos, Madrid, Spain" "etiqueta" => "e" "identificador" => "aff0025" ] 5 => array:3 [ "entidad" => "Servicio de Reumatología, Hospital Regional Universitario de Málaga, Málaga, Spain" "etiqueta" => "f" "identificador" => "aff0030" ] 6 => array:3 [ "entidad" => "Servicio de Neumología, Hospital Universitario Lucus Augusti, Lugo, Spain" "etiqueta" => "g" "identificador" => "aff0035" ] 7 => array:3 [ "entidad" => "Servicio de Reumatología, Hospital Universitario de la Santa Creu i Sant Pau, Barcelona, Spain" "etiqueta" => "h" "identificador" => "aff0040" ] 8 => array:3 [ "entidad" => "Servicio de Neumología, Hospital Universitario Galdakao-Usansolo, Bilbao, Spain" "etiqueta" => "i" "identificador" => "aff0045" ] 9 => array:3 [ "entidad" => "Servicio de Reumatología, Hospital Universitario La Paz, Madrid, Spain" "etiqueta" => "j" "identificador" => "aff0050" ] 10 => array:3 [ "entidad" => "Hospital Universitario de Canarias, San Cristóbal de la Laguna, Santa Cruz de Tenerife, Spain" "etiqueta" => "k" "identificador" => "aff0055" ] 11 => array:3 [ "entidad" => "Servicio de Reumatología, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain" "etiqueta" => "l" "identificador" => "aff0060" ] 12 => array:3 [ "entidad" => "Servicio de Reumatología, Hospital Universitario Quironsalud de Pozuelo, Pozuelo de Alarcón, Madrid, Spain" "etiqueta" => "m" "identificador" => "aff0065" ] 13 => array:3 [ "entidad" => "Servicio de Reumatología, Hospital General Universitario Gregorio Marañón, Madrid, Spain" "etiqueta" => "n" "identificador" => "aff0070" ] 14 => array:3 [ "entidad" => "Servicio de Reumatología, Hospital Virgen del Puerto, Plasencia, Cáceres, Spain" "etiqueta" => "o" "identificador" => "aff0075" ] 15 => array:3 [ "entidad" => "Servicio de Reumatología, Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain" "etiqueta" => "p" "identificador" => "aff0080" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Recomendaciones SER-SEPAR para el manejo de la enfermedad pulmonar intersticial difusa asociada a la artritis reumatoide. Parte 1: epidemiología, factores de riesgo y pronóstico" ] ] "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">Rheumatoid arthritis (RA) is an immune-mediated systemic inflammatory disease that primarily affects the joints and causes joint destruction, impaired functional capacity, and quality of life, and may even reduce life expectancy. It is the most prevalent form of chronic polyarthritis in Spain with the greatest social and health impact. According to data from the EPISER study, RA has an estimated prevalence of .82% in the Spanish adult population.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">In addition to joint damage, in a variable percentage of cases the disease presents with different extra-articular manifestations, including pulmonary manifestations. The spectrum of respiratory complications caused by RA is very broad and includes pleural involvement, rheumatoid pulmonary nodules (including Caplan syndrome), interstitial lung disease (ILD) and follicular or obliterative bronchiolitis.<a class="elsevierStyleCrossRefs" href="#bib0010"><span class="elsevierStyleSup">2,3</span></a> Bronchiectasis, primary pulmonary hypertension, secondary amyloidosis, thromboembolic disease, and cricoarytenoid arthritis have been reported more rarely.</p><p id="par0015" class="elsevierStylePara elsevierViewall">ILD is one of the most frequent and severe pulmonary complications of RA.<a class="elsevierStyleCrossRefs" href="#bib0020"><span class="elsevierStyleSup">4,5</span></a> The risk of RA patients developing this complication is almost 9 times higher than in the general population.<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">6</span></a> Furthermore, although there has been a significant improvement in prognosis in the last 25 years, <span class="elsevierStyleSup">7</span> ILD is still the second leading cause of death from the disease, accounting for 10%–20% of deaths. This clinical fact warrants a common strategy between rheumatologists and pneumologists to improve the prognosis and quality of life of patients with this complication.</p><p id="par0020" class="elsevierStylePara elsevierViewall">For this reason, the Spanish Societies of Rheumatology (SER) and Pneumology and Thoracic Surgery (SEPAR) promoted the drafting of a joint document of recommendations for the management of RA-ILD based on the best available evidence, with the aim of answering most of the common clinical questions, reducing the variability in medical care and facilitating decision-making for clinicians directly involved in the care of the condition.</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Methods</span><p id="par0025" class="elsevierStylePara elsevierViewall">A qualitative synthesis of the scientific evidence and consensus techniques was used in the drafting of these recommendations, which reflect the agreement of experts based on the available evidence and their clinical experience.<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">8</span></a></p><p id="par0030" class="elsevierStylePara elsevierViewall">The procedure for developing the project was as follows:<ul class="elsevierStyleList" id="lis0005"><li class="elsevierStyleListItem" id="lsti0005"><span class="elsevierStyleLabel">1</span><p id="par0035" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic">Creation of the working group</span>. An interdisciplinary working group was formed by 5 rheumatologists from SER (JN, GB, IC, NMV, and AMO) and 5 pneumologists from SEPAR (MA, ECJ, MAN, CV, and JARP). The participants were endorsed by their society to participate in this document. The clinical and methodological aspects were coordinated, respectively, by one of the rheumatologists (JN) and a pneumologist (JARP), as principal investigators (PI), and two methodology specialists from the SER Research Unit.</p></li><li class="elsevierStyleListItem" id="lsti0010"><span class="elsevierStyleLabel">2</span><p id="par0040" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic">Identification of key areas</span>. The content and key aspects of the document were defined, and the clinical research questions with the greatest impact on clinical practice were formulated. The questions were reformulated in patient, intervention, comparison, and outcome (PICO) format.</p></li><li class="elsevierStyleListItem" id="lsti0015"><span class="elsevierStyleLabel">3</span><p id="par0045" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic">Literature search</span>. A search for published scientific evidence was conducted and progressively expanded until October 2020. The databases PubMed (MEDLINE), EMBASE, and Cochrane Library (Wiley Online) were used for this purpose. The process was completed with a manual search of the references of the studies identified, as well as posters and conference abstracts that the reviewers and experts considered to be of interest.</p></li><li class="elsevierStyleListItem" id="lsti0020"><span class="elsevierStyleLabel">4</span><p id="par0050" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic">Analysis and synthesis of the scientific evidence</span>. Rheumatologists from SER who are experts in evidence review conducted the systematic reviews and synthesis of the scientific evidence. The level of scientific evidence was assessed using Scottish Intercollegiate Guidelines Network (SIGN)<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">9</span></a> criteria (Appendix B Annex).</p></li><li class="elsevierStyleListItem" id="lsti0025"><span class="elsevierStyleLabel">5</span><p id="par0055" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic">Formulation of recommendations</span>. Once the critical reading had been completed, the PIs, together with the members of the expert group reviewing the evidence for each of the PICO questions, formulated the recommendations, based on formal evaluation or "reasoned judgement" of the evidence for each of the questions. The quality, quantity, and consistency of the scientific evidence, the generalisability, applicability, and clinical impact of the results were considered. The strength of the recommendations was graded using the SIGN<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">7</span></a> system. For questions where the evidence was insufficient, recommendations were formulated based on consensus of the expert group.</p><p id="par0060" class="elsevierStylePara elsevierViewall">The recommendations have been divided into five main areas: incidence and prevalence of ILD in RA, risk factors for the onset of ILD in RA, prognostic factors for mortality and pulmonary progression, as well as the safety of drug treatment in patients with RA-ILD, and its efficacy in managing this complication.</p><p id="par0065" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic">External review.</span> The draft document was subjected to external review to ensure the validity and accuracy of the recommendations and, subsequently, to public exposure so that other SER and SEPAR members, as well as different groups and potentially interested entities, could evaluate the document, and offer criticism or suggestions.</p></li></ul></p></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">General preliminary considerations</span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">Identification of the type of RA-associated ILD</span><p id="par0070" class="elsevierStylePara elsevierViewall">The most common histological types of RA-ILD are usual interstitial pneumonia (UIP) and non-specific interstitial pneumonia (NSIP).<a class="elsevierStyleCrossRefs" href="#bib0010"><span class="elsevierStyleSup">2–7</span></a> The UIP pattern is as frequent or more frequent than NSIP. Other patterns described are organising pneumonia (OP), lymphoid interstitial pneumonia (LIP), diffuse alveolar damage (DAD), acute fibrinous and organising pneumonia (AFOP), desquamative interstitial pneumonia (DIP), respiratory bronchiolitis associated with interstitial lung disease and the combined pulmonary fibrosis + emphysema (CPFE) pattern.<a class="elsevierStyleCrossRefs" href="#bib0010"><span class="elsevierStyleSup">2–7,10</span></a> These last three patterns are included in the spectrum of smoking-related lung lesions,<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">11</span></a> although they have also been described in patients with RA who are non-smokers.<a class="elsevierStyleCrossRefs" href="#bib0060"><span class="elsevierStyleSup">12,13</span></a></p><p id="par0075" class="elsevierStylePara elsevierViewall">The ILD pattern must be correctly identified because of its therapeutic and prognostic implications, since the more inflammatory patterns (cellular NSIP, OP, LIP) will respond better to anti-inflammatory and immunosuppressive treatment than UIP.</p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Diagnosis of RA-ILD</span><p id="par0080" class="elsevierStylePara elsevierViewall">If ILD is suspected (presence of cough and/or dyspnoea of more than 3 months duration or velcro-like crackles on respiratory auscultation), a chest X-ray and lung function test (LFT) including spirometry and diffusing capacity of the lungs for carbon monoxide (DLCO) are usually performed for initial screening. In general, chest X-ray is a very insensitive technique in the early stages. In ILD, spirometry shows restrictive ventilatory impairment together with decreased DLCO. However, in early stages, it is not uncommon for decreased DLCO to be the only abnormality present.</p><p id="par0085" class="elsevierStylePara elsevierViewall">High-resolution computed tomography (HRCT) of the chest to confirm ILD is the gold standard for the diagnosis of this complication. The radiological pattern on HRCT correlates well with the histological pattern in most cases, and therefore a lung biopsy is usually not necessary. HRCT is also useful to quantify the extent of parenchymal involvement (alveolitis/fibrosis), to determine the potential reversibility of the lesions (alveolitis/fibrosis), to establish a prognosis (UIP vs. non-UIP) and to assess response to treatment.</p><p id="par0090" class="elsevierStylePara elsevierViewall">Disease activity and response to treatment is monitored with LFTs (spirometry and plethysmography to assess forced vital capacity [FVC], DLCO and total lung capacity), the 6-minute walk test and assessment of dyspnoea with one of the different clinical scales. Chest HRCT is usually only repeated in cases where it is necessary to assess functional deterioration, treatment readjustments or if exacerbation, infection, or other respiratory complications, such as lung cancer, are suspected.</p><p id="par0095" class="elsevierStylePara elsevierViewall">In advanced stages, Doppler echocardiography is also useful to detect onset of secondary pulmonary arterial hypertension.</p><p id="par0100" class="elsevierStylePara elsevierViewall">Bronchoalveolar lavage is not routinely performed. It is only indicated if it helps in the differential diagnosis, primarily with infections. Lung biopsy is only performed if there is suspicion of non-RA-ILD, doubts about the presence of other entities such as neoplasms or infection, or to establish a histo-specific diagnosis in atypical cases.</p><p id="par0105" class="elsevierStylePara elsevierViewall">The differential diagnosis of ILD is mainly infection, pulmonary drug toxicity, thromboembolic disease, heart failure, or lung cancer (fundamentally in smokers).</p></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Definition of progressive fibrosing ILD</span><p id="par0110" class="elsevierStylePara elsevierViewall">A variable percentage of patients with RA-ILD (around 40% at 5 years after ILD diagnosis)<a class="elsevierStyleCrossRefs" href="#bib0070"><span class="elsevierStyleSup">14–16</span></a> develop progressive pulmonary fibrosis with severe deterioration of lung function, rapid progression to chronic respiratory failure, and high mortality. There is no standard or agreed definition of what is considered progressive fibrosing ILD. The randomised clinical trial INBUILD<a class="elsevierStyleCrossRef" href="#bib0085"><span class="elsevierStyleSup">17</span></a> used the following four criteria to define progression in patients with fibrosing ILD: 1) a decrease in baseline FVC > 10% of the percentage of the estimated theoretical value; 2) a decrease in FVC of between 5%–10% with evidence of progressive fibrosing on chest HRCT; 3) a decrease in FVC of between 5%–10% with worsening respiratory symptoms (dyspnoea and dry cough), or 4) a worsening of dyspnoea with progressive fibrosing on HRCT in the previous 24 months despite treatment.</p><p id="par0115" class="elsevierStylePara elsevierViewall">Some experts also define progression as a decrease in FVC between 5%–10% with a worsening of DLCO greater than 15%.<a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">18</span></a></p><p id="par0120" class="elsevierStylePara elsevierViewall">According to the INBUILD study,<a class="elsevierStyleCrossRef" href="#bib0085"><span class="elsevierStyleSup">17</span></a> fibrosing ILD is defined as fibrosis changes affecting more than 10% of the lung parenchyma.</p><p id="par0125" class="elsevierStylePara elsevierViewall">However, and according to the classic definitions of the American Society of Pulmonology, worsening of any type of ILD (fibrosing or non-fibrosing) is defined as a decrease in FVC (expressed as a percentage of the predicted value) greater than 10% or a decrease in DLCO greater than 15% during follow-up.<a class="elsevierStyleCrossRefs" href="#bib0095"><span class="elsevierStyleSup">19,20</span></a></p></span></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">Results</span><p id="par0130" class="elsevierStylePara elsevierViewall">A total of 18 recommendations have been formulated. This article contextualises the six recommendations made following the systematic literature review (SLR) of the epidemiology, risk factors, and prognosis of RA-ILD (<a class="elsevierStyleCrossRef" href="#tbl0005">Table1</a>).</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0135" class="elsevierStylePara elsevierViewall">For further information on any of the sections summarised in this article, the full content of the document can be accessed on the SER website (<a href="http://www.ser.es">www.ser.es</a>).</p><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0100">Epidemiology of RA-ILD</span><p id="par0140" class="elsevierStylePara elsevierViewall">— <span class="elsevierStyleItalic">What is the incidence and prevalence of RA-IDP in patients with RA?</span><ul class="elsevierStyleList" id="lis0010"><li class="elsevierStyleListItem" id="lsti0030"><span class="elsevierStyleLabel">□</span><p id="par0145" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic">Recommendation</span>. Based on its incidence and prevalence, it is recommended that the possibility of ILD should always be considered in the initial assessment and follow-up of patients with RA (recommendation grade √).</p></li></ul></p><p id="par0150" class="elsevierStylePara elsevierViewall">It is vital to establish the prevalence and incidence of ILD in RA. Knowing the magnitude of this complication is essential to define strategies for early diagnosis and treatment, and good health planning.</p><p id="par0155" class="elsevierStylePara elsevierViewall">The scientific evidence for this recommendation was based on an SLR in which the population was adult subjects, the intervention was a diagnosis of RA according to ACR 1987 or ACR/EULAR 2010 criteria, and the outcome was the incidence or prevalence of ILD diagnosed by chest HRCT scan and/or lung biopsy.</p><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0105">Incidence of RA-associated ILD</span><p id="par0160" class="elsevierStylePara elsevierViewall">The incidence of RA-associated ILD is 1.056 cases per 1000 patients (1.452 in males and .677 in females) according to a study conducted in a Japanese population (IORRA cohort) between 2004 and 2007.<a class="elsevierStyleCrossRef" href="#bib0105"><span class="elsevierStyleSup">21</span></a></p><p id="par0165" class="elsevierStylePara elsevierViewall">Outside the body of evidence, two other studies have been identified that evaluate the incidence in the Caucasian population, although the condition was not diagnosed with HRCT in all cases. In the study by Koduri et al.,<a class="elsevierStyleCrossRef" href="#bib0110"><span class="elsevierStyleSup">22</span></a> conducted in an English cohort of patients with RA onset, this complication was only investigated in the presence of respiratory symptoms or signs as part of routine clinical care practice. After a follow-up of 3 years, the incidence of ILD was 4.1 per 1000 patients. In another prospective population-based cohort study (Rochester, Minnesota) the cumulative incidence of ILD at 10, 20, and 30 years was 3.5, 6.3, and 7.7%, respectively.<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">6</span></a> In this study, the risk of RA patients developing this complication was much higher than that of the general population (HR: 8.96).</p></span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0110">Prevalence/frequency of RA-ILD</span><p id="par0170" class="elsevierStylePara elsevierViewall">Eleven articles have been identified in which all patients diagnosed with RA (consecutive unselected patients) were screened for ILD.<a class="elsevierStyleCrossRefs" href="#bib0115"><span class="elsevierStyleSup">23–33</span></a> The main results of these studies are shown in <a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>. The frequency of this complication shows great variability, ranging from 11.9% to 55.7%. This variability can be explained by the differences between the populations studied (great heterogeneity in demographic characteristics, time since onset, and degree of disease activity, frequency of smoking and percentage of patients with respiratory symptoms) and by the lack of uniformity in the HRCT findings used to establish a diagnosis of ILD.</p><elsevierMultimedia ident="tbl0010"></elsevierMultimedia><p id="par0175" class="elsevierStylePara elsevierViewall">Of the eleven articles identified, three included patients with RA of less than two years' duration.<a class="elsevierStyleCrossRefs" href="#bib0125"><span class="elsevierStyleSup">25–27</span></a>In these studies, the variability of the prevalence of ILD is lower and ranges from 27.5% to 41.8%, with higher figures in populations with a higher frequency of smoking.<a class="elsevierStyleCrossRefs" href="#bib0125"><span class="elsevierStyleSup">25,26</span></a></p><p id="par0180" class="elsevierStylePara elsevierViewall">In the eight studies conducted in patients with established RA (more than two years since onset)<a class="elsevierStyleCrossRefs" href="#bib0115"><span class="elsevierStyleSup">23,24,28–33</span></a> there is wide disparity in the frequency figures, even between the two studies that investigated this question prospectively.<a class="elsevierStyleCrossRefs" href="#bib0115"><span class="elsevierStyleSup">23,24</span></a> Thus, Bilgici et al.,<a class="elsevierStyleCrossRef" href="#bib0115"><span class="elsevierStyleSup">23</span></a> in a cohort of 52 unselected RA patients from a single centre in Turkey, found chest CT changes consistent with ILD in 55.7%. Dawson et al.,<a class="elsevierStyleCrossRef" href="#bib0120"><span class="elsevierStyleSup">24</span></a> in a cohort of 150 consecutive RA patients in two hospitals in the North of England, describe findings of "fibrosing alveolitis", a term comparable to UIP and fibrosing NSIP patterns, in 19% of cases. In general, and predictably, in these eight studies, the higher the percentage of patients included with respiratory symptoms, the higher the frequency of ILD.</p><p id="par0185" class="elsevierStylePara elsevierViewall">Outside the body of evidence, in a prospective study conducted in Spain in patients with RA onset without respiratory symptoms in which only those with radiographic or LFT abnormalities underwent chest HRCT, the prevalence of confirmed ILD at disease diagnosis was 5%, increasing to 7.5% at 5 years since onset.<a class="elsevierStyleCrossRef" href="#bib0170"><span class="elsevierStyleSup">34</span></a> These figures are lower than those reported in a Chinese cohort in which the frequency of ILD at diagnosis was 9.76%, increasing to 30.9% at 5-year follow-up.<a class="elsevierStyleCrossRef" href="#bib0175"><span class="elsevierStyleSup">35</span></a></p><p id="par0190" class="elsevierStylePara elsevierViewall">However, if we only consider the frequency of symptomatic or clinically significant RA-ILD (which is not the issue raised in the research question), the prevalence by HRCT in several landmark studies is between 10% and 29%.<a class="elsevierStyleCrossRefs" href="#bib0180"><span class="elsevierStyleSup">36–39</span></a> Finally, the prevalence of ILD in the only autopsy study to investigate this complication is 35%.<a class="elsevierStyleCrossRef" href="#bib0200"><span class="elsevierStyleSup">40</span></a></p></span></span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0115">Risk factors for onset of ILD in RA</span><p id="par0195" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic">— In patients with RA, what are the risk factors for onset of ILD?</span><ul class="elsevierStyleList" id="lis0015"><li class="elsevierStyleListItem" id="lsti0035"><span class="elsevierStyleLabel">□</span><p id="par0200" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic">Recommendation.</span> Patients with RA should be systematically screened for ILD in cases with respiratory symptoms or if velcro-like crackles are heard (recommendation grade √).</p></li><li class="elsevierStyleListItem" id="lsti0040"><span class="elsevierStyleLabel">□</span><p id="par0205" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic">Recommendation.</span> In cases without respiratory symptoms and with normal auscultation, the need for screening should be assessed individually according to the number of risk factors for onset of this complication, regardless of the time since onset of RA (recommendation grade √).</p></li><li class="elsevierStyleListItem" id="lsti0045"><span class="elsevierStyleLabel">□</span><p id="par0210" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic">Recommendation.</span> The presence of ILD should always be considered when deciding on treatment, given the potential risk of pneumonitis described with some of the drugs commonly used in RA (recommendation grade √).</p></li><li class="elsevierStyleListItem" id="lsti0050"><span class="elsevierStyleLabel">□</span><p id="par0215" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic">Recommendation.</span> In patients with RA, none of the investigational serum biomarkers tested so far has been shown to have better predictive value for the onset of ILD than ACPA antibodies. Based on the current evidence, the drafting group does not recommend the use of other serum biomarkers in routine clinical practice (recommendation grade D).</p></li></ul></p><p id="par0220" class="elsevierStylePara elsevierViewall">Despite its frequency and severity, to date there are no recommendations on screening for this complication, in either the initial assessment or in the follow-up of RA patients. However, as mentioned above, when the entire RA population was screened for ILD by HRCT, a non-negligible percentage of subclinical disease was detected (between 11.9% and 55.7%), confirming that it is underdiagnosed. In fact, in clinical practice, it is not uncommon for ILD to be diagnosed late, as it is often asymptomatic or pseudo-symptomatic in its early stages.</p><p id="par0225" class="elsevierStylePara elsevierViewall">Therefore, knowing the main risk factors associated with the onset of RA-ILD will help us identify the subgroup of patients at greatest risk of developing this complication who may benefit from specific screening to diagnose them early (even if they do not have respiratory symptoms or signs).</p><p id="par0230" class="elsevierStylePara elsevierViewall">According to the results of the SLR, the main risk factors for the onset of RA-ILD are:<ul class="elsevierStyleList" id="lis0020"><li class="elsevierStyleListItem" id="lsti0055"><span class="elsevierStyleLabel">1</span><p id="par0235" class="elsevierStylePara elsevierViewall">Male sex<a class="elsevierStyleCrossRefs" href="#bib0175"><span class="elsevierStyleSup">35,41</span></a> (level of evidence 2+).</p></li><li class="elsevierStyleListItem" id="lsti0060"><span class="elsevierStyleLabel">2</span><p id="par0240" class="elsevierStylePara elsevierViewall">Advanced age and late onset of the disease (level of evidence 2++).<a class="elsevierStyleCrossRefs" href="#bib0160"><span class="elsevierStyleSup">32,35,36,42</span></a><span class="elsevierStyleSup">,</span><a class="elsevierStyleCrossRef" href="#bib0215"><span class="elsevierStyleSup">43</span></a> No cut-off point is established in most studies, except two: >60 years (OR: 1.48; 95% CI: 1.01–2.18)<a class="elsevierStyleCrossRef" href="#bib0175"><span class="elsevierStyleSup">35</span></a> and ≥65 years (RR: 4.58; 95% CI: 1.67–12.53).<a class="elsevierStyleCrossRef" href="#bib0210"><span class="elsevierStyleSup">42</span></a></p></li><li class="elsevierStyleListItem" id="lsti0065"><span class="elsevierStyleLabel">3</span><p id="par0245" class="elsevierStylePara elsevierViewall">Duration of the disease, onset of ILD being more frequent during the first 5–10 years of RA progression<a class="elsevierStyleCrossRefs" href="#bib0140"><span class="elsevierStyleSup">28,32,35</span></a> (level of evidence 2+).</p></li><li class="elsevierStyleListItem" id="lsti0070"><span class="elsevierStyleLabel">4</span><p id="par0250" class="elsevierStylePara elsevierViewall">Smoking<a class="elsevierStyleCrossRefs" href="#bib0160"><span class="elsevierStyleSup">32,36,44,45</span></a> (level of evidence 2++). Smoking and smoking rate are strongly associated with onset of ILD, with an OR: 3.76 (95% CI: 1.59–8.88) in the case of having smoked ≥25 pack-years and 1.9 (95% CI: .68–5.24) if less than 25 pack/years.<a class="elsevierStyleCrossRef" href="#bib0220"><span class="elsevierStyleSup">44</span></a> Several studies indicate that smokers’ increased risk of developing ILD is associated with the presence of the shared epitope, showing that there is an important gene-environment interaction between the shared epitope alleles and smoking.<a class="elsevierStyleCrossRefs" href="#bib0005"><span class="elsevierStyleSup">1,42,44</span></a></p></li><li class="elsevierStyleListItem" id="lsti0075"><span class="elsevierStyleLabel">5</span><p id="par0255" class="elsevierStylePara elsevierViewall">Moderate or high sustained RA activity<a class="elsevierStyleCrossRef" href="#bib0225"><span class="elsevierStyleSup">45</span></a> (level of evidence 2++). Patients with moderate/high maintained disease activity according to DAS28-CRP scores are at twice the risk of developing ILD than patients in remission or with low disease activity (results adjusted for sex, smoking, RA duration, and serostatus: HR: 2.22; 95% CI: 1.28–3.82).<a class="elsevierStyleCrossRef" href="#bib0225"><span class="elsevierStyleSup">45</span></a> The risk of ILD in the different disease activity statuses is as follows: low disease activity (DAS28 > 2.6–3.2) 1.41 (95% CI: .61–3.28), moderate disease activity (>3.2-5.1) 2.08 (95% CI: 1.06–4.05), and high disease activity (>5.1) 3.48 (95% CI: 1.64–7.38).<a class="elsevierStyleCrossRef" href="#bib0225"><span class="elsevierStyleSup">45</span></a></p></li><li class="elsevierStyleListItem" id="lsti0080"><span class="elsevierStyleLabel">6</span><p id="par0260" class="elsevierStylePara elsevierViewall">RF positivity (level of evidence 2++) and, especially, ACPA positivity (level of evidence 1+), especially at high titres.<a class="elsevierStyleCrossRefs" href="#bib0050"><span class="elsevierStyleSup">10,32,35,46–48</span></a> In a meta-analysis (which included 7 studies with 1685 patients; I<span class="elsevierStyleSup">2</span>: 0%), the risk of ILD and pulmonary fibrosis in the presence of ACPA was almost 5 times higher (OR: 4.68; 95% CI: 2.07–10.57).<a class="elsevierStyleCrossRef" href="#bib0230"><span class="elsevierStyleSup">46</span></a></p></li></ul></p><p id="par0265" class="elsevierStylePara elsevierViewall">In addition to RF and ACPA, the usefulness of other potential biomarkers predictive of the onset of ILD is being investigated, most notably antibodies directed against carbamylated proteins (anti-CarP). A correlation has been demonstrated between levels of all anti-CarP specificities (foetal calf serum, fibrinogen, and chimeric fibrine/filagrine homocitrullinated peptide) and the presence of ILD, after adjustment for other known risk factors<a class="elsevierStyleCrossRef" href="#bib0245"><span class="elsevierStyleSup">49</span></a> (level of evidence 3). Promising preliminary results have also been obtained with serum levels of extracellular matrix metalloproteinase 7 (MMP-7), interferon gamma-inducible protein-10 [IP-10] or CXCL10, interleukin-18, and 90- and 70-KDa heat shock proteins (HSP90/70)<a class="elsevierStyleCrossRefs" href="#bib0250"><span class="elsevierStyleSup">50–53</span></a> (level of evidence 2). None of these are yet available in clinical practice, nor have they as yet been shown to have greater predictive value for the development of this complication than ACPAs.</p><p id="par0270" class="elsevierStylePara elsevierViewall">Likewise, some genetic biomarkers have been identified, including mutations in the MUC5B gene<a class="elsevierStyleCrossRef" href="#bib0270"><span class="elsevierStyleSup">54</span></a> (which encodes one of the proteins of the mucin family) (level of evidence 2+) and mutations in the telomerase genes that cause accelerated telomere shortening<a class="elsevierStyleCrossRefs" href="#bib0275"><span class="elsevierStyleSup">55,56</span></a> (in cases with a family history of ILD) (level of evidence 2+).</p><p id="par0275" class="elsevierStylePara elsevierViewall">Finally, onset of ILD has also been linked to some of the drugs commonly used in the treatment of this disease. This issue is reviewed in depth in the second part of the recommendations, also published in this journal.</p><p id="par0280" class="elsevierStylePara elsevierViewall">To avoid late diagnosis of ILD in RA patients, the drafting group recommends regular questioning about the presence of respiratory symptoms and auscultation at least once a year for dry velcro-like crackles. The presence of velcro-like crackles correlates well with the presence of pulmonary fibrosis.<a class="elsevierStyleCrossRef" href="#bib0285"><span class="elsevierStyleSup">57</span></a> In addition, two studies have shown that conventional respiratory auscultation is acceptably diagnostically accurate to detect ILD compared to digital stethoscope.<a class="elsevierStyleCrossRefs" href="#bib0290"><span class="elsevierStyleSup">58,59</span></a></p><p id="par0285" class="elsevierStylePara elsevierViewall">The group also considers that patients with respiratory symptoms (cough and/or dyspnoea of more than 3 months' duration in the absence of known underlying pulmonary disease or pre-existing heart disease) should be routinely screened, and all those with velcro-like crackles detected on auscultation, even if asymptomatic. In asymptomatic patients with normal auscultation, the need for ILD screening will be assessed on an individual basis according to the number of risk factors for onset of the complication, regardless of time since onset of RA.</p></span><span id="sec0060" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0120">Risk factors for onset of RA-ILD</span><p id="par0290" class="elsevierStylePara elsevierViewall">— <span class="elsevierStyleItalic">What are the prognostic factors for mortality and progression of Lund disease in patients with RA-ILD?</span><ul class="elsevierStyleList" id="lis0025"><li class="elsevierStyleListItem" id="lsti0085"><span class="elsevierStyleLabel">□</span><p id="par0295" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic">Recommendation:</span> In patients with RA and ILD, it is recommended that the presence of prognostic factors associated with progression and mortality be considered when planning follow-up (frequency of check-ups) and treatment strategy (recommendation grade B).</p></li></ul></p><p id="par0300" class="elsevierStylePara elsevierViewall">ILD remains the second leading cause of premature death in RA, after cardiovascular complications.<a class="elsevierStyleCrossRefs" href="#bib0010"><span class="elsevierStyleSup">2–7</span></a> Approximately half of patients have stable or very slowly progressive ILD, whereas in the other half lung function deteriorates more or less rapidly.<a class="elsevierStyleCrossRefs" href="#bib0300"><span class="elsevierStyleSup">60,61</span></a> This heterogeneity in the course of the disease makes it essential to identify prognostic factors for severe disease and mortality. The SLR identified factors associated with progression of ILD and factors associated with increased mortality in patients with RA-ILD.</p><span id="sec0065" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0125">Predictors of RA-ILD progression</span><p id="par0305" class="elsevierStylePara elsevierViewall"><ul class="elsevierStyleList" id="lis0030"><li class="elsevierStyleListItem" id="lsti0090"><span class="elsevierStyleLabel">□</span><p id="par0310" class="elsevierStylePara elsevierViewall">Radiological pattern of UIP: the risk of progression in patients with UIP is approximately three times higher than in patients with NINE<a class="elsevierStyleCrossRefs" href="#bib0080"><span class="elsevierStyleSup">16,35</span></a> (level of evidence 2+).</p></li><li class="elsevierStyleListItem" id="lsti0095"><span class="elsevierStyleLabel">□</span><p id="par0315" class="elsevierStylePara elsevierViewall">Elevated ACPA titres (3 times above the upper limit of normal) with an OR of 4.03 (95% CI: 1.04–15.6)<a class="elsevierStyleCrossRef" href="#bib0310"><span class="elsevierStyleSup">62</span></a> (level of evidence 2+).</p></li><li class="elsevierStyleListItem" id="lsti0100"><span class="elsevierStyleLabel">□</span><p id="par0320" class="elsevierStylePara elsevierViewall">The degree of baseline DLCO deterioration,<a class="elsevierStyleCrossRefs" href="#bib0175"><span class="elsevierStyleSup">35,62,63</span></a> having been demonstrated with two cut-off points: DLCO < 45% (percentage of predicted value) (OR: 3.02; 95% CI: 1.13–8.03)<a class="elsevierStyleCrossRef" href="#bib0175"><span class="elsevierStyleSup">35</span></a> and, only in patients with a progressive fibrosing phenotype, DLCO < 54%: (OR: .85; 95% CI: .74–.98)<a class="elsevierStyleCrossRef" href="#bib0315"><span class="elsevierStyleSup">63</span></a> (level of evidence 2+).</p></li><li class="elsevierStyleListItem" id="lsti0105"><span class="elsevierStyleLabel">□</span><p id="par0325" class="elsevierStylePara elsevierViewall">In patients with UIP pattern, a drop ≥10% in FVC during follow-up (OR: .89; 95% CI: .82–.97) (level of evidence 2+).<a class="elsevierStyleCrossRef" href="#bib0320"><span class="elsevierStyleSup">64</span></a></p></li><li class="elsevierStyleListItem" id="lsti0110"><span class="elsevierStyleLabel">□</span><p id="par0330" class="elsevierStylePara elsevierViewall">Overall, the risk of progression of ILD increases the lower the baseline DLCO values, and the greater the worsening of FVC and/or DLCO during follow-up<a class="elsevierStyleCrossRef" href="#bib0080"><span class="elsevierStyleSup">16</span></a> (level of evidence 2+).</p></li><li class="elsevierStyleListItem" id="lsti0115"><span class="elsevierStyleLabel">□</span><p id="par0335" class="elsevierStylePara elsevierViewall">Extensive distribution on fibrotic changes on HRCT, principally traction bronchiectasis (≥ 4 lung areas affected with > 50% of the subpleural total)<a class="elsevierStyleCrossRef" href="#bib0325"><span class="elsevierStyleSup">65</span></a> (level of evidence 2++).</p></li><li class="elsevierStyleListItem" id="lsti0120"><span class="elsevierStyleLabel">□</span><p id="par0340" class="elsevierStylePara elsevierViewall">Elevated serum levels of IL-6 and KL-6 (level of evidence 2+).<a class="elsevierStyleCrossRefs" href="#bib0320"><span class="elsevierStyleSup">64,66</span></a></p></li></ul></p></span><span id="sec0070" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0130">Prognostic factors for mortality in RA-ILD</span><p id="par0345" class="elsevierStylePara elsevierViewall">Patients with RA-ILD have a 3- to 10-fold higher adjusted mortality risk than RA patients without the complication, regardless of the follow-up period and the presence of comorbidities<a class="elsevierStyleCrossRefs" href="#bib0030"><span class="elsevierStyleSup">6,67,68</span></a> (level of evidence 2+).</p><p id="par0350" class="elsevierStylePara elsevierViewall">The main prognostic factors for mortality identified in the SLR are:<ul class="elsevierStyleList" id="lis0035"><li class="elsevierStyleListItem" id="lsti0125"><span class="elsevierStyleLabel">□</span><p id="par0355" class="elsevierStylePara elsevierViewall">Advanced age at diagnosis of ILD<a class="elsevierStyleCrossRefs" href="#bib0110"><span class="elsevierStyleSup">22,35,60,62</span></a><span class="elsevierStyleSup">,</span><a class="elsevierStyleCrossRefs" href="#bib0320"><span class="elsevierStyleSup">64,67,69–72</span></a>: no cut-off point is established in most of the studies found, except three: >60 years (HR: 3.18; 95% CI: 1.27 to 7.94<a class="elsevierStyleCrossRef" href="#bib0175"><span class="elsevierStyleSup">35</span></a> and HR: 2.32; 95% CI: 1.27 to 4.25<a class="elsevierStyleCrossRef" href="#bib0310"><span class="elsevierStyleSup">62</span></a>) and ≥65 years (OR: 1.08; 95% CI: 1.02–1.15)<a class="elsevierStyleCrossRef" href="#bib0350"><span class="elsevierStyleSup">70</span></a> (level of evidence 2+).</p></li><li class="elsevierStyleListItem" id="lsti0130"><span class="elsevierStyleLabel">□</span><p id="par0360" class="elsevierStylePara elsevierViewall">Male gender<a class="elsevierStyleCrossRefs" href="#bib0335"><span class="elsevierStyleSup">67,73,74</span></a>: men have 3.6- to 14.5-fold higher mortality than women with this complication<a class="elsevierStyleCrossRef" href="#bib0335"><span class="elsevierStyleSup">67</span></a> (level of evidence 2+).</p></li><li class="elsevierStyleListItem" id="lsti0135"><span class="elsevierStyleLabel">□</span><p id="par0365" class="elsevierStylePara elsevierViewall">Duration of RA<a class="elsevierStyleCrossRefs" href="#bib0300"><span class="elsevierStyleSup">60,75</span></a>: the longer the duration of disease at diagnosis of ILD, the higher the mortality (HR per decade: 1.81; 95% CI: 1.16–2.83)<a class="elsevierStyleCrossRef" href="#bib0300"><span class="elsevierStyleSup">60</span></a> (level of evidence 2+).</p></li><li class="elsevierStyleListItem" id="lsti0140"><span class="elsevierStyleLabel">□</span><p id="par0370" class="elsevierStylePara elsevierViewall">Moderate or high disease activity (DAS28-VSG >3.2) is also associated with increased mortality (OR: 1.6; 95% CI 1.0–2.5).<a class="elsevierStyleCrossRef" href="#bib0375"><span class="elsevierStyleSup">75</span></a></p></li><li class="elsevierStyleListItem" id="lsti0145"><span class="elsevierStyleLabel">□</span><p id="par0375" class="elsevierStylePara elsevierViewall">Radiological pattern of UIP<a class="elsevierStyleCrossRefs" href="#bib0345"><span class="elsevierStyleSup">69,70,73,74</span></a><span class="elsevierStyleSup">,</span><a class="elsevierStyleCrossRefs" href="#bib0380"><span class="elsevierStyleSup">76,77</span></a>: according to the conclusions of a recent meta-analysis that included 10 retrospective studies with 1.256 patients with RA-ILD (I<span class="elsevierStyleSup">2</span>: 76%),<a class="elsevierStyleCrossRef" href="#bib0380"><span class="elsevierStyleSup">76</span></a> the UIP pattern has a mortality risk almost 2 times higher than non-UIP patterns (RR: 1.66; 95% CI: 1.07–2.76) (level of evidence 1++). In analysis by subgroups, when the UIP pattern was compared with the NSIP pattern the RR was 2.39 (95% CI: .86–6.68) and 1.45 (95% CI: .89 to 2.37) when the UIP was compared with other non-NSIP patterns. Increased mortality has also been described with a probable UIP pattern<a class="elsevierStyleCrossRef" href="#bib0385"><span class="elsevierStyleSup">77</span></a> (level of evidence 2+) and, in general, with all the forms of fibrosing RA-ILD (HR: 2.1; 95% CI: 1.11–4.26)<a class="elsevierStyleCrossRef" href="#bib0345"><span class="elsevierStyleSup">69</span></a> (level of evidence 2+).</p></li></ul></p><p id="par0380" class="elsevierStylePara elsevierViewall">It is important to highlight that in two studies<a class="elsevierStyleCrossRefs" href="#bib0300"><span class="elsevierStyleSup">60,78</span></a> the radiological pattern is no longer a predictor of mortality after adjustment for confounding variables in multivariate analysis, the main prognostic factors being the degree of baseline deterioration in respiratory function tests (FVC and DLCO) and the magnitude of their worsening during follow-up.<ul class="elsevierStyleList" id="lis0040"><li class="elsevierStyleListItem" id="lsti0150"><span class="elsevierStyleLabel">□</span><p id="par0385" class="elsevierStylePara elsevierViewall">A low baseline DLCO or a decrease in DLCO > 15% during follow-up (level of evidence 2++).<a class="elsevierStyleCrossRefs" href="#bib0300"><span class="elsevierStyleSup">60,61,71–73,76,79</span></a> Only the study by Zamora-Legoff et al.<a class="elsevierStyleCrossRef" href="#bib0300"><span class="elsevierStyleSup">60</span></a> establishes a cut-off point for baseline DLCO, setting it at less than 40% (HR: 2.48; 95% CI: 1.55–3.95) (level of evidence 2+). The prognostic value of baseline DLCO is independent of the presence or absence of emphysema due to smoking<a class="elsevierStyleCrossRef" href="#bib0380"><span class="elsevierStyleSup">76</span></a> (level of evidence 1++).</p></li><li class="elsevierStyleListItem" id="lsti0155"><span class="elsevierStyleLabel">□</span><p id="par0390" class="elsevierStylePara elsevierViewall">A low baseline FVC during follow-up (HR: 2.57; 95% CI: 1.79–3.70) (level of evidence 1++) or a decrease in FVC > 10%<a class="elsevierStyleCrossRefs" href="#bib0305"><span class="elsevierStyleSup">61,71,76</span></a> (level of evidence 2+). These studies do not establish a cut-off point for baseline FVC.</p></li><li class="elsevierStyleListItem" id="lsti0160"><span class="elsevierStyleLabel">□</span><p id="par0395" class="elsevierStylePara elsevierViewall">Extensive lung involvement on thoracic HRCT has been demonstrated when more than 20% of the lung parenchyma is involved<a class="elsevierStyleCrossRefs" href="#bib0050"><span class="elsevierStyleSup">10,80,81</span></a> (level of evidence 2++), and when more than 30% is involved 30%<a class="elsevierStyleCrossRefs" href="#bib0305"><span class="elsevierStyleSup">61,71</span></a> (level of evidence 2+).</p></li><li class="elsevierStyleListItem" id="lsti0165"><span class="elsevierStyleLabel">□</span><p id="par0400" class="elsevierStylePara elsevierViewall">Elevated serum levels of KL-6, which are associated with higher mortality (3–4 times higher)<a class="elsevierStyleCrossRefs" href="#bib0320"><span class="elsevierStyleSup">64,74</span></a> (level of evidence 2+).</p></li></ul></p><p id="par0405" class="elsevierStylePara elsevierViewall">Finally, the usefulness of the GAP index (calculated with gender, age, and FVC and DLCO values) to predict the risk of mortality at 1, 2 and 3 years in patients with RA-ILD has been demonstrated<a class="elsevierStyleCrossRefs" href="#bib0300"><span class="elsevierStyleSup">60,82</span></a> (level of evidence 2+). The CPI score<a class="elsevierStyleCrossRef" href="#bib0415"><span class="elsevierStyleSup">83</span></a> (level of evidence 2+) also appears to be useful for this purpose.</p></span></span></span><span id="sec0075" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0135">Discussion</span><p id="par0410" class="elsevierStylePara elsevierViewall">RA-ILD is a complex clinical situation, both because of its frequency and potential severity, and because of the difficulty in its therapeutic management. There is little published evidence on the subject, most is of low methodological quality, and with contradictory results in some aspects. There are also no recommendations yet agreed upon by scientific societies.</p><p id="par0415" class="elsevierStylePara elsevierViewall">This why we present the first official document drawn up by the SER and SEPAR with specific recommendations for the management of RA-ILD, which aims to serve as a guide for professionals caring for these patients and to bring clinical practice in line with the best possible evidence. These recommendations have been reached through a strict and validated methodology of systemic reviews of the scientific literature and expert consensus techniques.</p><p id="par0420" class="elsevierStylePara elsevierViewall">Epidemiological information is essential to measure the socio-health importance of diseases and to contribute to proper health planning. Therefore, one of the main objectives of the paper was to determine the prevalence and incidence of ILD in RA patients. However, the SLR revealed great variability in the studies that have investigated this issue, and therefore its actual frequency could not be reliably established. As a guideline, the prevalence of symptomatic ILD diagnosed by chest HRCT varies between 10% and 29%,<a class="elsevierStyleCrossRefs" href="#bib0180"><span class="elsevierStyleSup">36–39</span></a> whereas its incidence varies between 1.05 and 4.1 cases per 1000 patients,<a class="elsevierStyleCrossRefs" href="#bib0105"><span class="elsevierStyleSup">21,22</span></a> and the risk of developing this complication in RA patients is much higher than in the general population.<a class="elsevierStyleCrossRefs" href="#bib0030"><span class="elsevierStyleSup">6,84</span></a></p><p id="par0425" class="elsevierStylePara elsevierViewall">In more than three-quarters of patients, ILD develops after RA has been diagnosed, usually in the first 5–10 years of disease progression.<a class="elsevierStyleCrossRefs" href="#bib0010"><span class="elsevierStyleSup">2–7,21,22,28</span></a><span class="elsevierStyleSup">,</span><a class="elsevierStyleCrossRefs" href="#bib0160"><span class="elsevierStyleSup">32,35,85</span></a> In these cases, it is not uncommon for it to be diagnosed late, since it is often asymptomatic in its initial stages or presents with few symptoms, and goes unnoticed until advanced stages, when the extent of fibrotic changes limits therapeutic possibilities and survival (UIP is the most frequent histopathological pattern in RA). Less frequently, ILD occurs at onset of RA or precedes the joint manifestations by months or years.<a class="elsevierStyleCrossRefs" href="#bib0010"><span class="elsevierStyleSup">2–7</span></a> This circumstance has been reported in up to 10%–14% of patients with RA and ILD and is not always present and is often confused with idiopathic forms, despite their different prognosis and treatment.<a class="elsevierStyleCrossRefs" href="#bib0340"><span class="elsevierStyleSup">68,86,87</span></a></p><p id="par0430" class="elsevierStylePara elsevierViewall">Although a significant improvement in prognosis has been observed over the last 25 years,<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">7</span></a> RA-ILD is still the second leading cause of premature death in RA, after cardiovascular complications.<a class="elsevierStyleCrossRefs" href="#bib0010"><span class="elsevierStyleSup">2–7</span></a> Patients with RA-ILD have an adjusted mortality risk 3–10 times higher than RA patients without this complication<a class="elsevierStyleCrossRefs" href="#bib0030"><span class="elsevierStyleSup">6,67</span></a> and their median survival from diagnosis of ILS varies from 2.6 to 8.1 years.<a class="elsevierStyleCrossRef" href="#bib0440"><span class="elsevierStyleSup">88</span></a></p><p id="par0435" class="elsevierStylePara elsevierViewall">Although ILD is a frequent and under-diagnosed complication with high morbidity and mortality, there are as yet no recommendations for screening. In the absence of studies supporting the cost-effectiveness of universal screening, a reasonable strategy would be to design a selective screening proposal based on patients’ clinical risk. This clinical risk would be defined by the presence of respiratory symptoms (cough and/or dyspnoea of an unrelated cause of more than 3 months' duration), by the presence of dry velcro-like crackles on respiratory auscultation, or by the number of risk factors for the patient developing this complication. This initiative towards a multidisciplinary approach to selective screening criteria to identify patients with RA and ILD early was launched as a joint collaboration between the SER and SEPAR as part of the RA-EPIDSER project.<a class="elsevierStyleCrossRef" href="#bib0445"><span class="elsevierStyleSup">89</span></a> A tool to enable early identification of these patients with good sensitivity will help improve their survival and quality of life.</p><p id="par0440" class="elsevierStylePara elsevierViewall">Another important point is that RA-ILD behaves heterogeneously in terms of its clinical course and prognosis. ILD will be stable or progress very slowly in approximately half of patients, while in the other half lung function deteriorates rapidly, especially in patients with fibrosing ILD.<a class="elsevierStyleCrossRefs" href="#bib0300"><span class="elsevierStyleSup">60,61</span></a> This heterogeneity in progression makes it essential to identify prognostic factors for pulmonary progression and mortality to detect patients with a more severe profile early, who will be candidates for specific treatment as soon as the diagnosis of ILD is confirmed and for close clinical follow-up. The main prognostic factors include UIP pattern, extensive lung involvement on chest HRCT, the severity of deterioration of FVC and DLCO at diagnosis of RA-ILD, and the extent that these parameters have worsened during follow-up.<a class="elsevierStyleCrossRefs" href="#bib0050"><span class="elsevierStyleSup">10,60,61,69–74,76,77,79–81</span></a> Apart from the clinical and functional variables already in use, it remains to be seen how useful some of the biomarkers under investigation are, mainly IL-6 and KL-6, will be as tools to help predict progression and mortality in the short and medium term. Although the prognostic predictive capacity of these biomarkers has been validated in some studies (most with a small sample size), their use in daily clinical practice is limited and international guidelines are reluctant to recommend their use<a class="elsevierStyleCrossRef" href="#bib0450"><span class="elsevierStyleSup">90</span></a> mainly due to the lack of efficiency studies demonstrating the cost-benefit compared to other currently used clinical and functional variables, the absence of consensus on the measurements that could be most useful, and the need for additional validation studies with a large number of patients.</p></span><span id="sec0080" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0140">Ethical responsibilities</span><p id="par0445" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleBold">Protection of humans and animals.</span> The authors declare that no experiments on humans or animals have been conducted for this research.</p><p id="par0450" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleBold">Data confidentiality.</span> The authors declare that no patient data appear in this article.</p><p id="par0455" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleBold">Right to privacy and informed consent.</span> The authors declare that no patient data appear in this article.</p></span><span id="sec0085" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0145">Funding</span><p id="par0460" class="elsevierStylePara elsevierViewall">This project was funded by the <span class="elsevierStyleGrantSponsor" id="gs0005">Spanish Society of Rheumatology</span> (SER) and the <span class="elsevierStyleGrantSponsor" id="gs0010">Spanish Society of Pneumology and Thoracic Surgery</span> (SEPAR).</p></span><span id="sec0090" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0150">Authorship</span><p id="par0465" class="elsevierStylePara elsevierViewall">All the authors made substantial contributions to a) the conception and design of the study and the data analysis, b) drafting of the article or critical review of the intellectual content, and c) final approval of the version presented.</p></span><span id="sec0095" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0155">Conflict of interests</span><p id="par0470" class="elsevierStylePara elsevierViewall">José Antonio Rodríguez Portal has received funding from Roche and Sanofi for attendance at courses/congresses; honoraria from Roche, Boehringer and Janssen for presentations; financial support from Bristol, Janssen, Roche, and Boehringer for consultancy for pharmaceutical companies and other technologies; and has participated in clinical trials funded by Gilead, Roche and Boehringer.</p><p id="par0475" class="elsevierStylePara elsevierViewall">Noé Brito García has no conflict of interests to declare.</p><p id="par0480" class="elsevierStylePara elsevierViewall">Petra Díaz del Campo Fontecha has no conflict of interests to declare.</p><p id="par0485" class="elsevierStylePara elsevierViewall">Claudia Valenzuela has received funding from Boehringer and Roche for attendance at courses/congresses; honoraria from Roche for presentations; and has received financial support from Boehringer, Galapagos, and Roche for consultancy for pharmaceutical companies and other technologies.</p><p id="par0490" class="elsevierStylePara elsevierViewall">Ana María Ortiz has received funding from Lilly, Novartis, Pfizer, Roche, Sandoz, Sanofi, and UCB for attending courses/congresses; honoraria from Abbvie, Lilly, MSD, and Roche for presentations; funding from Bristol, Gilead, MSD, and Roche for participating in research, and has received financial support from Abbvie, Gilead, Janssen, Lilly, and Pfizer for consultancy for pharmaceutical companies and other technologies. She has also participated in clinical trials for MSD/Amgen and Bristol.</p><p id="par0495" class="elsevierStylePara elsevierViewall">María Asunción Nieto has received funding from Boehringer, MSD, Roche, and TEVA for attending courses/congresses; honoraria from Boehringer, BMS, and Roche for presentations and for educational programmes or courses; funding from Boehringer and Roche for participating in research; and has received financial support from Roche, Boehringer, and Astra for consultancy for pharmaceutical companies and other technologies.</p><p id="par0500" class="elsevierStylePara elsevierViewall">Natalia Mena Vázquez has received funding from Abbvie, Novartis, Pfizer, and Roche for attending courses/congresses; honoraria from Abbvie, MSD, Pfizer, and Roche for presentations; and has received funding from Abbvie and MSD for educational programmes and courses.</p><p id="par0505" class="elsevierStylePara elsevierViewall">Esteban Cano Jiménez has received funding from Boehringer and Roche for attendance at courses/congresses; honoraria from Boehringer, Chiesi, Roche, and Rovi for presentations; and has received financial support from Galapagos for consultancy for pharmaceutical companies and other technologies.</p><p id="par0510" class="elsevierStylePara elsevierViewall">Iván Castellví has received funding from Actelion, BMS, Boheringer, Kern, Lilly, Novartis, Pfizer, and Sanofi for attendance at courses/congresses; honoraria from Actelion, BMS Boehringer, Nordic, Pfizer, and Roche for presentations; funding from Actelion for educational programmes and courses, and has received financial support from Actelion, Boehringer, Gebro, and Kern for consultancy for pharmaceutical companies and other technologies.</p><p id="par0515" class="elsevierStylePara elsevierViewall">Myriam Aburto has received funding from Boehringer and Roche for attendance at courses/congresses; honoraria from BMS, Boehringer, and Roche for presentations; and financial support from Boehringer for consultancy for pharmaceutical companies and other technologies. She has also participated in a Boehringer clinical trial.</p><p id="par0520" class="elsevierStylePara elsevierViewall">Gema Bonilla has received funding from Abbvie and Janssen for attendance at courses/congresses and honoraria from Abbvie, BMS, Boehringer, Novartis, Roche, and UCB for presentations.</p><p id="par0525" class="elsevierStylePara elsevierViewall">María Vanesa Hernández has no conflict of interests to declare.</p><p id="par0530" class="elsevierStylePara elsevierViewall">Félix Manuel Francisco Hernández has no conflict of interests to declare.</p><p id="par0535" class="elsevierStylePara elsevierViewall">María Correyero Plaza has no conflict of interests to declare.</p><p id="par0540" class="elsevierStylePara elsevierViewall">Isabel Castrejón has no conflict of interests to declare.</p><p id="par0545" class="elsevierStylePara elsevierViewall">Miguel Ángel Abad Hernández has no conflict of interests to declare.</p><p id="par0550" class="elsevierStylePara elsevierViewall">Javier Narváez has received funding from Bristol, Kern, Lilly, Pfizer, Roche, and Sanofi for attendance at courses/congresses; honoraria from Abbvie, Bristol, Boehringer, Gebro pharma, GSK, Kern, Lilly, Pfizer, Sanofi, and Sobi for presentations and consultancies for pharmaceutical companies and other technologies, and has participated in clinical trials funded by Boehringer, GSK, Janssen, Roche, and Vorso.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:15 [ 0 => array:3 [ "identificador" => "xres1779544" "titulo" => "Abstract" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0005" "titulo" => "Objective" ] 1 => array:2 [ "identificador" => "abst0010" "titulo" => "Methods" ] 2 => array:2 [ "identificador" => "abst0015" "titulo" => "Results" ] 3 => array:2 [ "identificador" => "abst0020" "titulo" => "Conclusions" ] ] ] 1 => array:2 [ "identificador" => "xpalclavsec1562300" "titulo" => "Keywords" ] 2 => array:3 [ "identificador" => "xres1779543" "titulo" => "Resumen" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0025" "titulo" => "Objetivo" ] 1 => array:2 [ "identificador" => "abst0030" "titulo" => "Métodos" ] 2 => array:2 [ "identificador" => "abst0035" "titulo" => "Resultados" ] 3 => array:2 [ "identificador" => "abst0040" "titulo" => "Conclusiones" ] ] ] 3 => array:2 [ "identificador" => "xpalclavsec1562301" "titulo" => "Palabras clave" ] 4 => array:2 [ "identificador" => "sec0005" "titulo" => "Introduction" ] 5 => array:2 [ "identificador" => "sec0010" "titulo" => "Methods" ] 6 => array:3 [ "identificador" => "sec0015" "titulo" => "General preliminary considerations" "secciones" => array:3 [ 0 => array:2 [ "identificador" => "sec0020" "titulo" => "Identification of the type of RA-associated ILD" ] 1 => array:2 [ "identificador" => "sec0025" "titulo" => "Diagnosis of RA-ILD" ] 2 => array:2 [ "identificador" => "sec0030" "titulo" => "Definition of progressive fibrosing ILD" ] ] ] 7 => array:3 [ "identificador" => "sec0035" "titulo" => "Results" "secciones" => array:3 [ 0 => array:3 [ "identificador" => "sec0040" "titulo" => "Epidemiology of RA-ILD" "secciones" => array:2 [ 0 => array:2 [ "identificador" => "sec0045" "titulo" => "Incidence of RA-associated ILD" ] 1 => array:2 [ "identificador" => "sec0050" "titulo" => "Prevalence/frequency of RA-ILD" ] ] ] 1 => array:2 [ "identificador" => "sec0055" "titulo" => "Risk factors for onset of ILD in RA" ] 2 => array:3 [ "identificador" => "sec0060" "titulo" => "Risk factors for onset of RA-ILD" "secciones" => array:2 [ 0 => array:2 [ "identificador" => "sec0065" "titulo" => "Predictors of RA-ILD progression" ] 1 => array:2 [ "identificador" => "sec0070" "titulo" => "Prognostic factors for mortality in RA-ILD" ] ] ] ] ] 8 => array:2 [ "identificador" => "sec0075" "titulo" => "Discussion" ] 9 => array:2 [ "identificador" => "sec0080" "titulo" => "Ethical responsibilities" ] 10 => array:2 [ "identificador" => "sec0085" "titulo" => "Funding" ] 11 => array:2 [ "identificador" => "sec0090" "titulo" => "Authorship" ] 12 => array:2 [ "identificador" => "sec0095" "titulo" => "Conflict of interests" ] 13 => array:2 [ "identificador" => "xack628935" "titulo" => "Acknowledgements" ] 14 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2021-12-22" "fechaAceptado" => "2022-02-07" "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec1562300" "palabras" => array:6 [ 0 => "Rheumatoid arthritis" 1 => "Diffuse interstitial lung disease" 2 => "Incidence" 3 => "Prevalence" 4 => "Risk factors" 5 => "Prognosis" ] ] ] "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec1562301" "palabras" => array:6 [ 0 => "Artritis reumatoide" 1 => "Enfermedad pulmonar intersticial difusa" 2 => "Incidencia" 3 => "Prevalencia" 4 => "Factores de riesgo" 5 => "Pronóstico" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:3 [ "titulo" => "Abstract" "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Objective</span><p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">To develop multidisciplinary recommendations to improve the management of rheumatoid arthritis-related interstitial lung disease (RA-ILD).</p></span> <span id="abst0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0015">Methods</span><p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">Clinical research questions relevant to the objective of the document were identified by a panel of rheumatologists and pneumologists selected based on their experience in the field. Systematic reviews of the available evidence were conducted, and evidence was graded according to the Scottish Intercollegiate Guidelines Network (SIGN) criteria. Specific recommendations were made.</p></span> <span id="abst0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0020">Results</span><p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">Six PICO questions were selected, three of which analysed the incidence and prevalence of RA-ILD, associated risk factors, and predictors of progression and mortality. A total of 6 specific recommendations on these topics, structured by question, were formulated based on the evidence found and/or expert consensus.</p></span> <span id="abst0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Conclusions</span><p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">We present the first official SER-SEPAR document with specific recommendations for RA-ILD management developed to resolve some common clinical questions and facilitate decision-making for patients.</p></span>" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0005" "titulo" => "Objective" ] 1 => array:2 [ "identificador" => "abst0010" "titulo" => "Methods" ] 2 => array:2 [ "identificador" => "abst0015" "titulo" => "Results" ] 3 => array:2 [ "identificador" => "abst0020" "titulo" => "Conclusions" ] ] ] "es" => array:3 [ "titulo" => "Resumen" "resumen" => "<span id="abst0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Objetivo</span><p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Elaborar unas recomendaciones multidisciplinares para mejorar el manejo de la enfermedad pulmonar intersticial difusa asociada a la artritis reumatoide (EPID-AR).</p></span> <span id="abst0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Métodos</span><p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">Un panel de reumatólogos y neumólogos expertos identificó preguntas clínicas de investigación relevantes para el objetivo del documento. Se realizaron revisiones sistemáticas de la evidencia, que se graduó de acuerdo con los criterios del <span class="elsevierStyleItalic">Scottish Intercollegiate Guidelines Network</span> (SIGN). Tras ello, se formularon las recomendaciones.</p></span> <span id="abst0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Resultados</span><p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">Se seleccionaron seis preguntas PICO, tres de las cuales específicamente evaluaron la incidencia y prevalencia de esta complicación, los factores de riesgo para su desarrollo, y los factores pronósticos de mortalidad y de progresión de la EPID-AR. Se formularon un total de 6 recomendaciones específicas sobre estos aspectos, estructuradas por pregunta, con base en la evidencia encontrada y/o consenso de expertos.</p></span> <span id="abst0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Conclusiones</span><p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">Se presenta el primer documento oficial SER-SEPAR de recomendaciones específicas para el abordaje la EPID-AR, con el fin de ayudar en la toma de decisiones a los clínicos directamente implicados en su manejo y aproximar la práctica asistencial a la mejor evidencia posible.</p></span>" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0025" "titulo" => "Objetivo" ] 1 => array:2 [ "identificador" => "abst0030" "titulo" => "Métodos" ] 2 => array:2 [ "identificador" => "abst0035" "titulo" => "Resultados" ] 3 => array:2 [ "identificador" => "abst0040" "titulo" => "Conclusiones" ] ] ] ] "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara" id="npar2005">Please cite this article as: Rodríguez Portal JA, Brito García N, Díaz del Campo Fontecha P, Valenzuela C, María Ortiz A, Nieto MA, et al. Recomendaciones SER-SEPAR para el manejo de la enfermedad pulmonar intersticial difusa asociada a la artritis reumatoide. Parte 1: epidemiología, factores de riesgo y pronóstico. Reumatol Clín. 2022;18:443–452.</p>" ] ] "apendice" => array:1 [ 0 => array:1 [ "seccion" => array:1 [ 0 => array:4 [ "apendice" => "<p id="par0575" class="elsevierStylePara elsevierViewall">The following is Supplementary data to this article:<elsevierMultimedia ident="upi0005"></elsevierMultimedia></p>" "etiqueta" => "Appendix A" "titulo" => "Supplementary data" "identificador" => "sec0105" ] ] ] ] "multimedia" => array:3 [ 0 => array:8 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0005" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:3 [ "leyenda" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">DLCO, diffusing capacity for carbon monoxide; FVC, forced vital capacity; HRCT, high-resolution computed tomography.</p>" "tablatextoimagen" => array:1 [ 0 => array:1 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Recommendations \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Recommendation grade \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Based on its incidence and prevalence, it is recommended that the possibility of interstitial lung disease should always be considered in the initial assessment and follow-up of patients with rheumatoid arthritis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">√ \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Patients with rheumatoid arthritis should be systematically screened for interstitial lung disease in cases with respiratory symptoms or if velcro-like crackles are heard \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">√ \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">In cases without respiratory symptoms and with normal auscultation, the need for screening should be assessed individually according to the number of risk factors<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a> for onset of this complication, regardless of the time since onset of rheumatoid arthritis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">√ \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">The presence of interstitial lung disease should always be considered when deciding on treatment, given the potential risk of pneumonitis described with some of the drugs commonly used in rheumatoid arthritis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">√ \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">In patients with rheumatoid arthritis, none of the investigational serum biomarkers tested so far has been shown to have better predictive value for the onset of interstitial lung disease than anti-citrullinated protein/peptide antibodies. Based on the current evidence, the drafting group does not recommend the use of other serum biomarkers in routine clinical practice \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">D \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">In patients with rheumatoid arthritis and interstitial lung disease it is recommended that the presence of prognostic factors associated with progression<a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">b</span></a> and mortality<a class="elsevierStyleCrossRef" href="#tblfn0015"><span class="elsevierStyleSup">c</span></a> be considered when planning follow-up (frequency of check-ups) and treatment strategy \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">B \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] ] ] "notaPie" => array:3 [ 0 => array:3 [ "identificador" => "tblfn0005" "etiqueta" => "a" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">The main risk factors for the development of interstitial lung disease, easily identifiable in the clinic, are male sex, older age, late disease onset, duration of rheumatoid arthritis, history of smoking, sustained moderate, or high disease activity, and rheumatoid factor and anti-citrullinated protein/peptide antibody positivity.</p>" ] 1 => array:3 [ "identificador" => "tblfn0010" "etiqueta" => "b" "nota" => "<p class="elsevierStyleNotepara" id="npar0010">The main predictors of progression of interstitial lung disease are the radiological pattern of usual interstitial pneumonia, elevated anti-citrullinated protein/peptide antibody titres, degree of baseline DLCO impairment, a ≥10% decrease (percentage of estimated theoretical value) in FVC during follow-up, extensive lung involvement on chest HRCT, and elevated serum levels of interleukin-6 and Krebs von den Lungen-6 glycoprotein.</p>" ] 2 => array:3 [ "identificador" => "tblfn0015" "etiqueta" => "c" "nota" => "<p class="elsevierStyleNotepara" id="npar0015">The main prognostic factors associated with increased mortality are advanced age at diagnosis of interstitial lung disease, male sex, duration of rheumatoid arthritis, moderate or high disease activity, the usual radiological pattern of interstitial pneumonia, low baseline FVC and/or DLCO, a decrease in FVC > 10% or DLCO > 15% during follow-up, extensive lung involvement on chest HRCT, GAP and CPI (composite physiologic index) indices, and elevated serum levels of Krebs von den Lungen-6 glycoprotein.</p>" ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">SER-SEPAR recommendations for the management of rheumatoid arthritis-associated interstitial lung disease: epidemiology, epidemiology, risk factors and prognosis of RA-ILD.</p>" ] ] 1 => array:8 [ "identificador" => "tbl0010" "etiqueta" => "Table 2" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0010" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "leyenda" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">ACPA: Anti-citrullinated Protein/peptide Antibodies; ILD: Interstitial Lung Disease; NS: Not specified; RF: Rheumatoid Factor.</p>" "tablatextoimagen" => array:1 [ 0 => array:1 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Study \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Country \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">N° of centres \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">N \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Age (years) \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Time since onset (years) \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Smoking (%) \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">RF (+)/ACPA (+) (%) \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Respiratory symptoms \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Frequency of ILD \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Bilgici et al.<a class="elsevierStyleCrossRef" href="#bib0115"><span class="elsevierStyleSup">23</span></a> (2005) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Turkey \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">52 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">53.6 ± 11.2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">8.37 ± 8.17 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">25% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">67.3%/NS \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Asymptomatic 59.6% (31/52) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">55.76% \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Symptomatic 21% (11) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Dawson et al.<a class="elsevierStyleCrossRef" href="#bib0120"><span class="elsevierStyleSup">24</span></a> (2001) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">UK \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">150 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">58.9 ± 10.3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">12.7 ± 8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">70% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">77%/NS \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Asymptomatic; 15 had crackles on respiratory auscultation (10%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">18.6% \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Mohd Noor et al.<a class="elsevierStyleCrossRef" href="#bib0140"><span class="elsevierStyleSup">28</span></a> (2009) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Malaysia \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">63 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">56.7 ± 10 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">14 ± 12 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">6% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">66.7%/NS \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Asymptomatic 67% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">44.4% \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Mori et al.<a class="elsevierStyleCrossRef" href="#bib0145"><span class="elsevierStyleSup">29</span></a> (2008) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Japan \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">126 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">60 ± 12.4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">61 patients with established RA (Time since onset: 11.8 ± 9.7) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">20% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">83%/93.8% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Patients with established RA: Asymptomatic 68.8% (42/61) Symptomatic 31.2% (19) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Total: 11.9% (15/126) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">65 patients with time since onset: 2.6 ± 4.5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Asymptomatic patients 83.1% (54/65) Symptomatic 16.9% (11) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">13.1% (8/61) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">10.7% (7/65) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Skare et al.<a class="elsevierStyleCrossRef" href="#bib0150"><span class="elsevierStyleSup">30</span></a> (2011) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Brazil \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">71 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">58.7 ± 10.4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">11.8 ± 6.9 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">35.8% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">704%/38% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Asymptomatic 44.75% (30/71) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">54.92% \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Symptomatic 55.25% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Wang y Du<a class="elsevierStyleCrossRef" href="#bib0155"><span class="elsevierStyleSup">31</span></a> (2015) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">China \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">544 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">NS \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n